Suven Life Sciences Limited

Equities

SUVEN

INE495B01038

Biotechnology & Medical Research

Market Closed - Bombay S.E. Other stock markets 06:00:48 2024-04-30 am EDT			5-day change	1st Jan Change
110.3 ^INR	-1.24%		+3.72%	+36.75%

Apr. 15	Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	CI
Feb. 06	Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	CI

Suven Life Sciences : Form MGT-7 FY 2022-23

July 15, 2023 at 08:51 am EDT

FORM NO. MGT-7

[Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of rule 11of the Companies (Management and Administration) Rules, 2014]

Form language

English

Hindi

Refer the instruction kit for filing the form.

Annual Return

(other than OPCs and Small Companies)

I. REGISTRATION AND OTHER DETAILS

* Corporate Identification Number (CIN) of the company Global Location Number (GLN) of the company

* Permanent Account Number (PAN) of the company

(a) Name of the company

(b) Registered office address

1. *e-mail ID of the company
2. *Telephone number with STD code
3. Website
Date of Incorporation

(iv)	Type of the Company	Category of the Company

Pre-fill

Sub-category of the Company

(v) Whether company is having share capital	Yes	No
(vi) *Whether shares listed on recognized Stock Exchange(s)	Yes	No

Page 1 of 15

(a) Details of stock exchanges where shares are listed

S. No.

Stock Exchange Name

Code

(b) CIN of the Registrar and Transfer Agent	Pre-fill
Name of the Registrar and Transfer Agent

Registered office address of the Registrar and Transfer Agents

(vii) *Financial year From date 01/04/2022	(DD/MM/YYYY) To date	31/03/2023	(DD/MM/YYYY)
(viii) *Whether Annual general meeting (AGM) held		Yes	No
	(a) If yes, date of AGM
	(b) Due date of AGM	30/09/2023
	(c) Whether any extension for AGM granted			Yes	No
II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY
	*Number of business activities	1

	S.No	Main	Description of Main Activity group	Business	Description of Business Activity		% of turnover
		Activity				Activity		of the
		group code				Code		company

		M				M5

PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES)

*No. of Companies for which information is to be given 2	Pre-fill All

S.No	Name of the company	CIN / FCRN	Holding/ Subsidiary/Associate/	% of shares held
			Joint Venture

Page 2 of 15

IV. SHARE CAPITAL, DEBENTURES AND OTHER SECURITIES OF THE COMPANY

(i) *SHARE CAPITAL

(a) Equity share capital

Particulars

Authorised

Issued

Subscribed

Paid up capital

capital

Total number of equity shares

300,000,000

218,073,717

Total amount of equity shares (in

300,000,000

218,073,717

Rupees)

Number of classes

Class of Shares

Authorised

Issued

Subscribed

capital

Paid up capital

Equity share

capital

Number of equity shares

300,000,000

218,073,717

Nominal value per share (in rupees)

Total amount of equity shares (in rupees)

300,000,000

218,073,717

(b) Preference share capital

Particulars

Authorised

Issued

Subscribed

Paid-up capital

capital

Total number of preference shares

Total amount of preference shares

(in rupees)

Number of classes

Class of shares

Authorised

Issued

Subscribed

capital

Paid up capital

capital

Number of preference shares

Nominal value per share (in rupees)

Total amount of preference shares (in rupees)

Particulars

Total amount of unclassified shares

Authorised Capital

(d) Break-up of paid-up share capital

				Total	Total	Total
Class of shares	Number of shares	nominal	Paid-up	premium
				amount	amount


Equity shares	Physical	DEMAT	Total

Page 3 of 15

At the beginning of the year	18,478,631 126,903,847 145382478 145,382,478 145,382,47


Increase during the year	0	90,838,706	90838706	72,691,239 72,691,239 0

i. Pubic Issues	0	0	0	0	0	0


ii. Rights issue	0	72,691,239	72691239	72,691,239 72,691,239


iii. Bonus issue	0	0	0	0	0	0


iv. Private Placement/ Preferential allotment	0	0	0	0	0	0


v. ESOPs	0	0	0	0	0	0


vi. Sweat equity shares allotted	0	0	0	0	0


vii. Conversion of Preference share	0	0	0	0	0	0


viii. Conversion of Debentures	0	0	0	0	0	0


ix. GDRs/ADRs	0	0	0	0	0	0


x. Others, specify		18,147,467	18147467

conversion of physical shares to demat shares


Decrease during the year	18,147,467	0	18147467	0	0	0


i. Buy-back of shares	0	0	0	0	0	0


ii. Shares forfeited	0	0	0	0	0	0


iii. Reduction of share capital	0	0	0	0	0	0


iv. Others, specify	18,147,467		18147467

conversion of physical shares to demat shares

At the end of the year	331,164	217,742,553	218073717 218,073,717 218,073,71

Preference shares

At the beginning of the year	0	0	0	0	0


Increase during the year	0	0	0	0	0	0


i. Issues of shares	0	0	0	0	0	0


ii. Re-issue of forfeited shares	0	0	0	0	0	0


iii. Others, specify


Decrease during the year	0	0	0	0	0	0

Page 4 of 15

	i. Redemption of shares			0		0	0	0		0	0


	ii. Shares forfeited			0		0	0	0		0	0


	iii. Reduction of share capital			0		0	0	0		0	0


	iv. Others, specify


	At the end of the year			0		0	0	0		0


ISIN of the equity shares of the company					INE495B01038
	(ii) Details of stock split/consolidation during the year (for each class of shares)		0


	Class of shares		(i)		(ii)				(iii)

	Before split /		Number of shares

	Consolidation
		Face value per share

	After split /		Number of shares

	Consolidation
		Face value per share

Details of shares/Debentures Transfers since closure date of last financial year (or in the case of the first return at any time since the incorporation of the company) *

Nil
[Details being provided in a CD/Digital Media]	Yes	No	Not Applicable
Separate sheet attached for details of transfers	Yes	No

Note: In case list of transfer exceeds 10, option for submission as a separate sheet attachment or submission in a CD/Digital Media may be shown.

Date of the previous annual general meeting

Date of registration of transfer (Date Month Year)

Type of transfer

1 - Equity, 2- Preference Shares,3 - Debentures, 4 - Stock

Page 5 of 15

Attachments

Original Link
Original Document
Permalink

Disclaimer

Suven Life Sciences Limited published this content on 15 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 July 2023 12:50:07 UTC.

Latest news about Suven Life Sciences Limited

Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	Apr. 15	CI
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	Feb. 06	CI
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024	Jan. 30	CI
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 30	CI
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 04	CI
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy	23-10-30	CI
Suven Pharma Appoints New Board and Management Team	23-09-29	CI
Suven Pharma Appoints Sudhir Kumar Singh as CEO	23-09-29	CI
Transcript : Suven Life Sciences Limited, Q1 2024 Earnings Call, Aug 10, 2023	23-08-10
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-08	CI
Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada	23-06-01	CI
Transcript : Suven Life Sciences Limited, Q4 2023 Earnings Call, May 26, 2023	23-05-25
Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-09	CI
Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-09	CI
Li & Fung considers options for $500 mln Asia healthcare arm, including a sale - sources	23-01-16	RE
Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type	22-11-16	CI
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10	CI
Transcript : Suven Life Sciences Limited, Q2 2023 Earnings Call, Nov 09, 2022	22-11-09
Suven Pharmaceuticals' Consolidated Net Profit Declines in Fiscal Q2	22-11-08	MT
Suven Life Sciences Gets Board Panel Nod for Rights Issue	22-10-14	MT
Suven Pharmaceuticals Board Declares Interim Dividend and Special Dividend for Fiscal 2023	22-09-02	MT
Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022	22-09-02	CI
Suven Pharmaceuticals Mulls Interim Dividend for Fiscal 2023	22-08-29	MT
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-07-26	CI
Suven Life Sciences Gets Board Approval to Raise Up to $51 Million Via Rights Issues	22-06-24	MT

Chart Suven Life Sciences Limited

Duration

Period

More charts

Company Profile

Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SUVEN LIFE SCIENCES LIMITED	+36.75%	288M
IQVIA HOLDINGS INC.	+1.98%	42.19B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+7.39%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-21.27%	18.2B
MEDPACE HOLDINGS, INC.	+30.38%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.28%	11.76B
UNITED THERAPEUTICS CORPORATION	+15.91%	10.4B
BIO-TECHNE CORPORATION	-3.89%	9.94B

Other Biotechnology & Medical Research